Arcus Biosciences, Inc. (NYSE:RCUS) CFO Sells $53,910.00 in Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CFO Robert C. Goeltz II sold 3,594 shares of the company’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total value of $53,910.00. Following the sale, the chief financial officer now owns 60,138 shares of the company’s stock, valued at $902,070. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Arcus Biosciences Stock Down 0.5 %

Shares of RCUS traded down $0.07 during mid-day trading on Friday, reaching $15.06. The company’s stock had a trading volume of 385,138 shares, compared to its average volume of 486,969. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. Arcus Biosciences, Inc. has a 1 year low of $13.52 and a 1 year high of $20.31. The business has a fifty day moving average of $15.94 and a 200 day moving average of $16.02. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -4.78 and a beta of 0.88.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.00) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.06. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company had revenue of $48.00 million during the quarter, compared to the consensus estimate of $38.95 million. During the same period last year, the business earned ($0.94) EPS. The business’s quarterly revenue was up 50.0% on a year-over-year basis. As a group, analysts forecast that Arcus Biosciences, Inc. will post -3.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Arcus Biosciences

A number of institutional investors have recently modified their holdings of the company. Jane Street Group LLC boosted its stake in Arcus Biosciences by 59.8% in the third quarter. Jane Street Group LLC now owns 217,041 shares of the company’s stock worth $3,319,000 after purchasing an additional 81,193 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Arcus Biosciences by 11.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company’s stock worth $8,669,000 after purchasing an additional 59,536 shares during the period. GSA Capital Partners LLP raised its holdings in shares of Arcus Biosciences by 17.8% in the third quarter. GSA Capital Partners LLP now owns 187,415 shares of the company’s stock valued at $2,866,000 after purchasing an additional 28,307 shares during the last quarter. Parkman Healthcare Partners LLC increased its position in shares of Arcus Biosciences by 146.9% in the third quarter. Parkman Healthcare Partners LLC now owns 1,025,754 shares of the company’s stock valued at $15,684,000 after acquiring an additional 610,219 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in Arcus Biosciences during the second quarter worth $1,286,000. Institutional investors own 92.89% of the company’s stock.

Analysts Set New Price Targets

RCUS has been the subject of a number of research reports. Wells Fargo & Company initiated coverage on shares of Arcus Biosciences in a research report on Tuesday, October 8th. They set an “overweight” rating and a $29.00 price target for the company. HC Wainwright reiterated a “neutral” rating and set a $20.00 target price on shares of Arcus Biosciences in a research note on Wednesday, November 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcus Biosciences in a research report on Thursday, October 3rd. Barclays upped their target price on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Finally, Wedbush restated an “outperform” rating and set a $36.00 price objective on shares of Arcus Biosciences in a research note on Thursday, November 7th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $34.00.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.